

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
11 November 2021 (11.11.2021)



(10) International Publication Number
WO 2021/226258 A1

(51) International Patent Classification:

A61K 9/20 (2006.01) A61P 1/16 (2006.01)
A61K 31/513 (2006.01) A61P 25/18 (2006.01)
A61K 47/20 (2006.01) C07D 239/54 (2006.01)

(21) International Application Number:

PCT/US2021/030923

(22) International Filing Date:

05 May 2021 (05.05.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/020,919 06 May 2020 (06.05.2020) US

(71) Applicant: **CORCEPT THERAPEUTICS INCORPORATED** [US/US]; 149 Commonwealth Drive, Menlo Park, California 94025 (US).

(72) Inventors: **CHIA, Yip-Fong**; c/o Corcept Therapeutics Incorporated, 149 Commonwealth Drive, Menlo Park, California 94025 (US). **ARBOLEDA, Stephen**; c/o Corcept Therapeutics Incorporated, 149 Commonwealth Drive, Menlo Park, California 94025 (US). **ALSMEYER, Yan**; c/o Corcept Therapeutics Incorporated, 149 Commonwealth Drive, Menlo Park, California 94025 (US). **DAVIS, Gordon**; c/o Corcept Therapeutics Incorporated, 149 Commonwealth Drive, Menlo Park, California 94025 (US). **CLIKE-**

MAN, Tyler; c/o Corcept Therapeutics Incorporated, 149 Commonwealth, Menlo Park, California 94025 (US).

(74) Agent: **TRIMBLE, Alexander, R.** et al.; Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C., One Financial Center, Boston, Massachusetts 02111 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: FORMULATIONS OF PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS

FIG. 1

Compound I Form B, XRPD Diffractogram



(57) Abstract: The present invention provides formulations of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione, and methods of making and using the same.

[Continued on next page]

WO 2021/226258 A1

Published:

— with international search report (Art. 21(3))